相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
Naval Daver et al.
BLOOD CANCER JOURNAL (2021)
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design
Almudena Aguilera-Diaz et al.
PLOS ONE (2020)
Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges
Gabriel C. Caponetti et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Characterization ofFLT3-ITDmutacute myeloid leukemia: molecular profiling of leukemic precursor cells
Serena Travaglini et al.
BLOOD CANCER JOURNAL (2020)
Utility and validation of a comprehensive cost-effective targeted DNA panel including FLT3-ITDs, CALR and CEBPA on a next-generation sequencing (NGS) platform for hematological malignancies
Meenakshi Ahluwalia et al.
CANCER RESEARCH (2020)
False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases
Young-Ho Kim et al.
PLOS ONE (2019)
CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay
Christopher Wai Siong Ng et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Internal tandem duplications in FLT3 detected by anchored multiplex PCR and next-generation sequencing
B. van Deusen et al.
ANNALS OF ONCOLOGY (2017)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Clinical Applications of Next-Generation Sequencing in Cancer Diagnosis
Leila Sabour et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
The Accurate Detection by Next-Generation Sequencing (NGS) of Difficult to Sequence Genes (CALR, CEBPA, FLT3) Associated With Myeloid Disorders Using a Hybridisation-Based Enrichment Approach
Graham Speight et al.
Cancer Genetics (2017)
Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology
Nicole M. Kuderer et al.
JAMA ONCOLOGY (2017)
Review of Clinical Next-Generation Sequencing
Sophia Yohe et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A Clinical Grade Sequencing-Based Assay for CEBPA Mutation Testing Report of a Large Series of Myeloid Neoplasms
Amir Behdad et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Long-term follow-up of cytogenetically normal CEBPA-mutated AML
Friederike Pastore et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity
Ulrike Bacher et al.
BLOOD (2012)
Strategy for Robust Detection of Insertions, Deletions, and Point Mutations in CEBPA, a GC-Rich Content Gene, Using 454 Next-Generation Deep-Sequencing Technology
Vera Grossmann et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
分享论文
